Covid-19: Europe struggling to bounce back
Environment and Risk Management
European markets are now facing counterbalancing risks: deflationary and default on one side - following the current Coronavirus shock and its effect on the real economy - and reflationary on the other - thanks to Central Banks and Governments' agendas aimed to get consumers and corporates through this uncertain period, providing stimulus in different shapes and forms. However, we still have concerns that market’s sentiment is somehow too optimistic, especially when assessing the strength of the rebound (the actual state of the real economy, the level of activity and, particularly, earnings’ forecasts for 2021). For example, when it comes to the Eurostoxx 50, 2021 consensus earnings were indeed in line with 2019 levels.
With this backdrop, our conviction is that markets will trade in wide, volatile ranges in the coming months. Therefore, we are adapting our asset allocation in order to be more liquid and more flexible.
As of lately, we have been actively managing the equity exposure while keeping a moderate level of equity investments (around 30%), focused on quality/growth stocks. However, currently, to reduce the equity exposure, we tend to have a preference for perfect hedges via derivatives, instead of selling short index futures - as we generally do - so to avoid any unwanted bias at the same time. In parallel, we also decided to take more risk through an active management of our credit exposure. We believe, in fact, that our credit component offers attractive valuation levels relative to fundamental risk.
The medium-term outlook remains very uncertain. There is a path in the western world for more of the same, thus taking the Japanese route: low growth, low interest rates for the foreseeable future, and ample liquidity supply. If this is the case, equity indices trade sideways, but high-quality growth stocks will keep outperforming. This is also our base case scenario and justifies our stock picking. But the macro risk in our opinion is to the downside, as economists might overestimate the recovery beyond the initial short-term relief, so that we are in fact heading for a prolonged recession. In such circumstances, the capacity of Central Banks to keep managing the environment would be challenged, and markets could be seriously destabilized once again. This risk asymmetry explains the reason why we maintain our overall cautious stance, despite the market rally. We therefore also decided to keep a higher than usual proportion of cash & cash equivalent.
Core Positioning
Equity: stick to our roadmapOur investment process is tilted towards quality/growth stocks, which we believe are well suited to navigate this uncertain environment. The ideas identified by our process are high-quality names in innovative fields like - among others - healthcare, biotech and selected industrials. To give context, it is interesting to note the increasing focus on the healthcare sector amidst the current pandemic. Even if its role within the current social structure has been only strengthened by the Covid-19 scare, in reality - within our equity pocket - it has been one of our long-term conviction and currently is the biggest sector exposure we have.
We maintain a low modified duration alongside an opportunistic credit portfolio:
Main risks of the Fund
EQUITY: The Fund may be affected by stock price variations, the scale of which is dependent on external factors, stock trading volumes or market capitalization. INTEREST RATE: Interest rate risk results in a decline in the net asset value in the event of changes in interest rates. CREDIT: Credit risk is the risk that the issuer may default. CURRENCY: Currency risk is linked to exposure to a currency other than the Fund’s valuation currency, either through direct investment or the use of forward financial instruments. The Fund presents a risk of loss of capital.
Source: Carmignac, 15/05/2020.
This document is intended for professional clients. This is an advertising document. This document may not be reproduced, in whole or in part, without prior authorisation from the management company. This document does not constitute a subscription offer, nor does it constitute investment advice. Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive. The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency hedged. Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. Access to the Fund may be subject to restrictions with regard to certain persons or countries. The Fund is not registered in North America, in South America, in Asia nor is it registered in Japan. The Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Fund has not been registered under the US Securities Act of 1933. The Fund may not be offered or sold, directly or indirectly, for the benefit or on behalf of a "U.S. person", according to the definition of the US Regulation S and/or FATCA. The Fund presents a risk of loss of capital. The risks and fees are described in the KIID (Key Investor Information Document). The Fund's prospectus, KIIDs and annual reports are available at www.carmignac.com, or upon request to the Management Company. The KIID must be made available to the subscriber prior to subscription. - In Switzerland, the Fund’s respective prospectuses, KIIDs and annual reports are available at www.carmignac.ch, or through our representative in Switzerland, CACEIS (Switzerland) S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Paris, succursale de Nyon/Suisse, Route de Signy 35, 1260 Nyon. - In the United Kingdom, the Funds’ respective prospectuses, KIIDs and annual reports are available at www.carmignac.co.uk, or upon request to the Management Company, or for the French Funds, at the offices of the Facilities Agent at BNP PARIBAS SECURITIES SERVICES, operating through its branch in London: 55 Moorgate, London EC2R. This material was prepared by Carmignac Gestion and/or Carmignac Gestion Luxembourg and is being distributed in the UK by Carmignac Gestion Luxembourg UK Branch (Registered in England and Wales with number FC031103, CSSF agreement of 10/06/2013) - In Spain: Carmignac Portfolio is registered with Comisión Nacional del Mercado de Valores de España (CNMV) under number 392. • Carmignac Gestion - 24 place Vendôme - F-75001 Paris. Tel: (+33) 01 42 86 53 35 - Investment management company approved by the AMF - Public limited company with share capital of € 15,000,000 - RCS Paris B 349 501 676. • Carmignac Gestion Luxembourg - City Link - 7 rue de la Chapelle - L-1325 Luxembourg - Tel: (+352) 46 70 601. Subsidiary of Carmignac Gestion - Investment fund management company approved by the CSSF - Public limited company with share capital of € 23,000,000 - RC Luxembourg B 67 549.